

Deregulation of the non-coding genome in leukemia

Susanna Teppo , Merja Heinäniemi & Olli Lohi

To cite this article: Susanna Teppo , Merja Heinäniemi & Olli Lohi (2017) Deregulation of the non-coding genome in leukemia, RNA Biology, 14:7, 827-830, DOI: [10.1080/15476286.2017.1312228](https://doi.org/10.1080/15476286.2017.1312228)

To link to this article: <http://dx.doi.org/10.1080/15476286.2017.1312228>



© 2017 The Author(s). Published with license by Taylor & Francis Group, LLC
Susanna Teppo, Merja Heinäniemi, and Olli Lohi



Accepted author version posted online: 07 Apr 2017.
Published online: 07 Apr 2017.



Submit your article to this journal [↗](#)



Article views: 277



View related articles [↗](#)



View Crossmark data [↗](#)

POINT OF VIEW



Deregulation of the non-coding genome in leukemia

Susanna Teppo ^a, Merja Heinäniemi ^b, and Olli Lohi ^a

^aTampere Center for Child Health Research, Faculty of Medicine and Life Sciences, University of Tampere and Tampere University Hospital, Tampere, Finland; ^bInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland

ABSTRACT

Methodological advances that allow deeper characterization of non-coding elements in the genome have started to reveal the full spectrum of deregulation in cancer. We generated an inducible cell model to track transcriptional changes after induction of a well-known leukemia-inducing fusion gene, ETV6-RUNX1. Our data revealed widespread transcriptional alterations outside coding elements in the genome. This adds to the growing list of various alterations in the non-coding genome in cancer and pinpoints their role in diseased cellular state.

ARTICLE HISTORY

Received 7 February 2017
Revised 21 March 2017
Accepted 24 March 2017

KEYWORDS

eRNA; GRO-seq; leukemia;
nascent RNA; transcriptional
regulation

Approximately 80 % of the genome is transcribed into RNA species in at least some cell type or at some stage of development.^{1,2} Non-coding regulatory (non-housekeeping) RNAs are currently defined by their size, genomic location or presumptive function. Enhancer RNAs (eRNA), which have a length span from 0.1 to 10 kb, mainly fall into the category of long non-coding RNAs (lncRNAs) although they are better defined by their transcriptional regulatory function. Larger clusters of enhancers with multiple transcription factor (TF) binding sites and open chromatin marks are termed super-enhancers and they define cell identity.^{3,4} Locations of enhancer elements are often deduced from certain histone marks (H3K4me1, H3K27ac), transcription factor binding profiles (p300), or open chromatin states (eg. DNase- and ATAC-seq). The development of global nascent RNA sequencing techniques, such as global run-on sequencing (GRO-seq),⁵ has revealed that transcription of eRNAs is highly correlated with marks such as H3K27ac (for review see ref. 6) and to transcription at nearby gene promoters,^{7,8} and is considered the most reliable mark of an active enhancer.^{7,9} The functions of eRNAs are yet unclear: they can be passive byproducts of transcription or function actively in recruitment of transcription factors (reviewed in ref. 10), like in the case of Yin-Yang (YY)1.¹¹

Misregulation of ncRNAs is common in cancer although recurrent structural variations have been challenging to find. For example, in a study with whole-genome sequencing of 150 tumor/normal pairs of chronic lymphocytic leukemia, only one recurrent non-coding mutation cluster was found at a potential regulatory element.¹² However, this may also reflect the lacking annotations. We recently analyzed whole genome sequencing data from precursor B-cell acute lymphoblastic leukemia (pre-B-ALL) in the context of chromatin architecture and found that the topologically associated domains with the

highest number of breakpoints contained unannotated ncRNAs.¹³ Functional studies manipulating lncRNA production in leukemia have shown diverse roles in cancer-related pathways.^{14–16} In addition, functional studies on enhancers have highlighted their overall role in cancer, as reviewed in ref. 17. In leukemia, somatic mutation of a non-coding element generated a MYB binding site upstream of oncogenic TAL1 locus, and a deletion of the mutated (but not wild type allele) super-enhancer in a T-ALL cell line decreased expression of TAL1 and impaired cell survival.¹⁸ Altered transcription at enhancers may also result from structural or quantitative changes in both enhancer elements and their regulating proteins. Duplication of NOTCH1-driven MYC enhancer was observed in T-ALL and its relevance demonstrated in a mouse knockout model.¹⁹ Moreover, aberrations in chromatin structure and especially in insulator regions induce abnormal gene expression, as exemplified by activation of TAL1 due to a deletion of upstream insulator element.²⁰ Misregulated transcription during delicate differentiation processes in haematopoietic precursors may also cause cancer by predisposing to secondary mutations. Convergent transcription and RNA polymerase II stalling strongly correlate with structural variation clusters and seem to provide vulnerable regions for RAG and AID mediated double strand breaks in lymphoma and leukemia.^{13,21} Although ncRNA expression profiles using microarray or RNA-seq have been published (eg. refs. 22–26), many nascent transcripts have remained unnoticed because of rapid degradation of several ncRNA species. New methods to address this challenge have emerged, such as GRO-seq, PRO-seq or TT-seq that enable monitoring various nascent transcripts and engaged RNA polymerase II in leukemia.^{27,28}

CONTACT Susanna Teppo  susanna.teppo@uta.fi  Tampere Center for Child Health Research, Faculty of Medicine and Life Sciences, University of Tampere, Laakarinkatu 1, Arvo, Tampere 33520, Finland.

Published with license by Taylor & Francis Group, LLC © Susanna Teppo, Merja Heinäniemi, and Olli Lohi

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.




Figure 1. (A) A schematic representation of the ETV6-RUNX1 (E/R, TEL-AML1) fusion protein resulting from a recurrent t(12;21) translocation in pediatric pre-B acute lymphoblastic leukemia. ETV6-RUNX1 includes the pointed (PNT) domain of ETS variant 6 (ETV6) but lacks the ETS domain that is involved in DNA binding of the normal TF protein. The 480 aa long RUNX1 variant 1 (AML-1c, NP_001745) is illustrated with the point mutation R201Q in the Runt domain which impedes its DNA binding capability (this was used to generate E/Rmut in ref. 30). ID = Runx inhibitory domain. (B) GRO-seq signal (nascent RNA transcription) is shown for E/R-negative as red and E/R-positive samples as blue tracks at an example genomic region. Signals above and below the axis indicate plus and minus strands, respectively. RUNX1 ChIP peaks in SEM cells (GSE42075, ref. 42) and an enhancer marker H3K4me1 ChIP-seq in B-cells (GM12878, ref. 2) are shown and coincide with the GRO-seq signal. Three enhancer regions that are downregulated by E/R via RUNX1-mediated binding are highlighted. Nalm6-E/R = 24h expression of E/R in a pre-B-ALL cell line; REH = E/R-positive cell line; pre-B-ALL other = E/R-negative patient; pre-B-ALL E/R+ = E/R-positive patient.

We addressed this issue in the ETV6-RUNX1 (E/R, TEL-AML1) fusion positive leukemia,³⁰ which represents 25 % of pediatric acute lymphoblastic leukemias, and causes alterations in gene expression that predispose to leukemia.²⁹ With the help of an inducible E/R cell model and GRO-seq, we explored dynamics of gene expression and the activity of their regulatory elements simultaneously, exposing the transcriptional circuitry downstream of the E/R fusion (Fig. 1).³⁰ We analyzed enhancers based on eRNA

correlation with GRO-seq signal change at differentially expressed genes (transcript-centric approach). Secondly, we generated an enhancer-centric approach that directly applied the statistical framework on eRNA levels to identify significantly regulated enhancers (enhancer annotation was based on H3K27ac and RUNX1 ChIP-seq data) and correlated these changes to that of nearby transcripts. We found at least one similarly altered putative enhancer element within ± 400 kb for almost all the deregulated coding transcripts using transcript-centric approach. E/R regulated approximately 20% of transcribed regions with RUNX1 ChIP peaks, and 5% of CD19/20 (B-cell)-related enhancers. Interestingly, CD19/20 specific super-enhancers were mostly downregulated, implying a way for E/R to arrest cell differentiation.




It has been proposed that any transcription may possess regulatory activity. A recent study showed that half of the studied transcribed gene loci (12 lncRNA and 6 mRNA) regulated a nearby gene in *cis* independently of whether the locus was a coding or non-coding one.³¹ As the non-coding genome is only weakly conserved,^{1,32} most non-coding regions may function in a way which is not dependent on the sequence of transcript itself but rather the sequence of its promoter or its location in the genome. In the case of E/R leukemia, we classified 57 deregulated novel lncRNAs (over 5 kb long) as either potential eRNAs or lncRNAs based on the GRO-seq signal. One fourth of the novel and 3 of 7 annotated transcripts were concordantly differentially expressed in RNA-seq data with 8 E/R-positive and 9 other subtype pre-B-ALL patients.³⁰ For example, KCNQ1OT1, which acts in epigenetic regulation,³³⁻³⁵ was upregulated in our E/R cell model GRO-seq and the patient RNA-seq data. Signal changes at ZEB1 and ZEB1-AS1 serve as an example of a simultaneous downregulation of gene and its promoter-associated RNA, with ZEB also being linked to cancer^{36,37} and late B cell differentiation.³⁸ Functional roles of the novel transcripts in E/R leukemia remains to be explored in future. Nascent RNA profiles of diagnostic patient samples of distinct ALL subtypes will give further insights into the detailed transcriptional network downstream of the oncogenic TF fusions.

Already, thousands of regulatory lncRNA transcripts³⁹ and hundreds of thousands of enhancer regions have been found. It is now known that ncRNAs are widely specific to a certain cell type and developmental stage. For example, most lncRNAs that are expressed at various stages of mouse B cell development are not expressed in a closely related T-cell lineage.⁴⁰ A recent study noted that distal regulatory elements varied across distinct haematopoietic lineages so that they are better discriminators of cell identity than mRNA levels.⁴¹ This was also reflected in our work, where we noticed that sample separation based on quantification of global eRNA transcription was equally good as that based on quantification of transcription at protein coding regions.³⁰ We can assume that the increasing knowledge of the interplay between various elements of genome and their transcriptional products will significantly contribute to our understanding of the diverse types of leukemia and cancer in near future.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

ORCID

Susanna Teppo  <http://orcid.org/0000-0003-2569-8030>
 Merja Heinäniemi  <http://orcid.org/0000-0001-6190-3439>
 Olli Lohi  <http://orcid.org/0000-0001-9195-0797>

References

1. ENCODE Project Consortium TEP, Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. *Nature* 2007; 447:799-816; PMID:17571346; <https://doi.org/10.1038/nature05874>
2. ENCODE Project Consortium TEP, Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M. An integrated encyclopedia of DNA elements in the human genome. *Nature* 2012; 489:57-74; PMID:22955616; <https://doi.org/10.1038/nature11247>
3. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA. Master transcription factors and mediator establish super-enhancers at key cell identity genes. *Cell* 2013; 153:307-19; PMID:23582322; <https://doi.org/10.1016/j.cell.2013.03.035>
4. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. Super-enhancers in the control of cell identity and disease. *Cell* 2013; 155:934-47; PMID:24119843; <https://doi.org/10.1016/j.cell.2013.09.053>
5. Core LJ, Waterfall JJ, Lis JT. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. *Science* 2008; 322:1845-8; PMID:19056941; <https://doi.org/10.1126/science.1162228>
6. Lam MTY, Li W, Rosenfeld MG, Glass CK. Enhancer RNAs and regulated transcriptional programs. *Trends Biochem Sci* 2014; 39:170-82; PMID:24674738; <https://doi.org/10.1016/j.tibs.2014.02.007>
7. Kaikkonen MU, Spann NJ, Heinz S, Romanoski CE, Allison KA, Stender JD, Chun HB, Tough DF, Prinjha RK, Benner C, et al. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. *Mol Cell* 2013; 51:310-25; PMID:23932714; <https://doi.org/10.1016/j.molcel.2013.07.010>
8. Kim T-K, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, Harmin DA, Laptevich M, Barbara-Haley K, Kuersten S, et al. Widespread transcription at neuronal activity-regulated enhancers. *Nature* 2010; 465:182-7; PMID:20393465; <https://doi.org/10.1038/nature09033>
9. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, Qiu J, Liu W, Kaikkonen MU, Ohgi KA, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. *Nature* 2011; 474:390-4; PMID:21572438; <https://doi.org/10.1038/nature10006>
10. Takemata N, Ohta K. Role of non-coding RNA transcription around gene regulatory elements in transcription factor recruitment. *RNA Biol* 2017; 14:1-5; PMID:27763805; <https://doi.org/10.1080/15476286.2016.1248020>
11. Sigova AA, Abraham BJ, Ji X, Molinier B, Hannett NM, Guo YE, Jangi M, Giallourakis CC, Sharp PA, Young RA. Transcription factor trapping by RNA in gene regulatory elements. *Science* (80-) 2015; 350:978-81; PMID:26516199; <https://doi.org/10.1126/science.1263346>
12. Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, Munar M, Rubio-Pérez C, Jares P, Aymerich M, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. *Nature* 2015; 526:519-24; PMID:26200345; <https://doi.org/10.1038/nature14666>
13. Heinäniemi M, Vuorenmaa T, Teppo S, Kaikkonen MU, Bouvy-Liivrand M, Mehtonen J, Niskanen H, Zachariadis V, Laukkanen S, Liuksiala T, et al. Transcription-coupled genetic instability marks acute lymphoblastic leukemia structural variation hotspots. *Elife* 2016; 5:e12068; PMID:26896675; <https://doi.org/10.7554/eLife.13087>
14. Blume CJ, Hotz-Wagenblatt A, Hülle J, Sellner L, Jethwa A, Stolz T, Slabicki M, Lee K, Sharathchandra A, Benner A, et al. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. *Leukemia* 2015; 29:2015-23; PMID:25971364; <https://doi.org/10.1038/leu.2015.119>
15. Guo G, Kang Q, Zhu X, Chen Q, Wang X, Chen Y, Ouyang J, Zhang L, Tan H, Chen R, et al. A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA. *Oncogene* 2015; 34:1768-79; PMID:24837367; <https://doi.org/10.1038/onc.2014.131>
16. Lu Y, Li Y, Chai X, Kang Q, Zhao P, Xiong J, Wang J. Long non-coding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia. *Gene* 2017; 607:41-6; PMID:28069548; <https://doi.org/10.1016/j.gene.2017.01.004>
17. Sur I, Taipale J. The role of enhancers in cancer. *Nat Rev Cancer* 2016; 16:483-93; PMID:27364481; <https://doi.org/10.1038/nrc.2016.62>
18. Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, et al. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. *Science* (80-) 2014; 346:1373-7; PMID:25394790; <https://doi.org/10.1126/science.1259037>
19. Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, Xu L, Castillo-Martin M, Llobet-Navás D, Cordon-Cardo C, et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. *Nat Med* 2014; 20:1130-7; PMID:25194570; <https://doi.org/10.1038/nm.3665>
20. Hnisz D, Weintraub AS, Day DS, Valton A-L, Bak RO, Li CH, Goldmann J, Lajoie BR, Fan ZP, Sigova AA, et al. Activation of proto-oncogenes by disruption of chromosome neighborhoods. *Science* (80-) 2016; 351:1454-8; PMID:26940867; <https://doi.org/10.1126/science.1269024>
21. Meng F-L, Du Z, Federation A, Hu J, Wang Q, Kieffer-Kwon K-R, Meyers RM, Amor C, Wasserman CR, Neuberger D, et al. Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability. *Cell* 2014; 159:1538-48; PMID:25483776; <https://doi.org/10.1016/j.cell.2014.11.014>
22. Fernando TR, Rodriguez-Malave NI, Waters EV, Yan W, Casero D, Basso G, Pigazzi M, Rao DS. LncRNA expression discriminates karyotype and predicts survival in B-lymphoblastic leukemia. *Mol Cancer Res* 2015; 13:839-51; PMID:25681502; <https://doi.org/10.1158/1541-7786.MCR-15-0006-T>
23. Nordlund J, Kiialainen A, Karlberg O, Berglund EC, Göransson-Kultima H, Sönderkaer M, Nielsen KL, Gustafsson MG, Behrendtz M, Forestier E, et al. Digital gene expression profiling of primary acute lymphoblastic leukemia cells. *Leukemia* 2012; 26:1218-27; PMID:22173241; <https://doi.org/10.1038/leu.2011.358>
24. Ghazavi F, De Moerloose B, Van Looke W, Wallaert A, Helsmoortel HH, Ferster A, Bakkus M, Plat G, Delabesse E, Uytendaele A, et al. Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia. *Oncotarget* 2016; 7:73769-80; PMID:27650541; <https://doi.org/10.18632/oncotarget.12063>
25. Teittinen KJ, Laiho A, Uusimäki A, Pursiheimo J-P, Gyenesei A, Lohi O. Expression of small nucleolar RNAs in leukemic cells. *Cell Oncol* 2013; 36:55-63; PMID:23229394; <https://doi.org/10.1007/s13402-012-0113-5>
26. Ronchetti D, Manzoni M, Agnelli L, Vinci C, Fabris S, Cutrona G, Matis S, Colombo M, Galletti S, Taiana E, et al. LncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. *Blood Cancer J* 2016; 6:e468; PMID:27611921; <https://doi.org/10.1038/bcj.2016.77>
27. Zhao Y, Liu Q, Acharya P, Stengel KR, Sheng Q, Zhou X, Kwak H, Fischer MA, Bradner JE, Strickland SA, et al. High-resolution mapping of RNA polymerases identifies mechanisms of sensitivity and

- resistance to BET inhibitors in t(8;21) AML. *Cell Rep* 2016; 16:2003-16; PMID:27498870; <https://doi.org/10.1016/j.celrep.2016.07.032>
28. Schwalb B, Michel M, Zacher B, Frühauf K, Demel C, Tresch A, Gagneur J, Cramer P. TT-seq maps the human transient transcriptome. *Science* (80-) 2016; 352:1225-8; PMID:27257258; <https://doi.org/10.1126/science.aad9841>
 29. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. *Lancet* 2013; 381:1943-55; PMID:23523389; [https://doi.org/10.1016/S0140-6736\(12\)62187-4](https://doi.org/10.1016/S0140-6736(12)62187-4)
 30. Teppo S, Laukkanen S, Liuksiala T, Nordlund J, Oittinen M, Teittinen K, Grönroos T, St-Onge P, Sinnett D, Syvänen A-C, et al. Genome-wide repression of eRNA and target gene loci by the ETV6-RUNX1 fusion in acute leukemia. *Genome Res* 2016; 26:1468-77; PMID:27620872; <https://doi.org/10.1101/gr.193649.115>
 31. Engreitz JM, Haines JE, Perez EM, Munson G, Chen J, Kane M, McDonel PE, Guttman M, Lander ES. Local regulation of gene expression by lncRNA promoters, transcription and splicing. *Nature* 2016; 539:452-5; PMID:27783602; <https://doi.org/10.1038/nature20149>
 32. Ponjavic J, Ponting CP, Lunter G. Functionality or transcriptional noise? Evidence for selection within long noncoding RNAs. *Genome Res* 2007; 17:556-65; PMID:17387145; <https://doi.org/10.1101/gr.6036807>
 33. Sunamura N, Ohira T, Kataoka M, Inaoka D, Tanabe H, Nakayama Y, Oshimura M, Kugoh H. Regulation of functional KCNQ1OT1 lncRNA by β -catenin. *Sci Rep* 2016; 6:20690; PMID:26868975; <https://doi.org/10.1038/srep20690>
 34. Ribarska T, Goering W, Droop J, Bastian K-M, Ingenwerth M, Schulz WA. Dereglulation of an imprinted gene network in prostate cancer. *Epigenetics* 2014; 9:704-17; PMID:24513574; <https://doi.org/10.4161/epi.28006>
 35. Pandey RR, Mondal T, Mohammad F, Enroth S, Redrup L, Komorowski J, Nagano T, Mancini-DiNardo D, Kanduri C. Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. *Mol Cell* 2008; 32:232-46; PMID:18951091; <https://doi.org/10.1016/j.molcel.2008.08.022>
 36. Lehmann W, Mossmann D, Kleemann J, Mock K, Meisinger C, Brummer T, Herr R, Brabletz S, Stemmler MP, Brabletz T. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. *Nat Commun* 2016; 7:10498; PMID:26876920; <https://doi.org/10.1038/ncomms10498>
 37. Zhang P, Sun Y, Ma L. ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. *Cell Cycle* 2015; 14:481-7; PMID:25607528; <https://doi.org/10.1080/15384101.2015.1006048>
 38. Malpeli G, Barbi S, Zupo S, Tosadori G, Scardoni G, Bertolaso A, Sartoris S, Ugel S, Vicentini C, Fassan M, et al. Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53. *Oncotarget* 2017; 8:11809-26; PMID:28107180; <https://doi.org/10.18632/oncotarget.14683>
 39. Hon C-C, Ramilowski JA, Harshbarger J, Bertin N, Rackham OJL, Gough J, Denisenko E, Schmeier S, Poulsen TM, Severin J, et al. An atlas of human long non-coding RNAs with accurate 5' ends. *Nature* 2017; 543:199-204; PMID:28241135; <https://doi.org/10.1038/nature21374>
 40. Brazão TF, Johnson JS, Müller J, Heger A, Ponting CP, Tybulewicz VJL. Long noncoding RNAs in B-cell development and activation. *Blood* 2016; 128:e10-9; PMID:27381906; <https://doi.org/10.1182/blood-2015-11-680843>
 41. Corces MR, Buenrostro JD, Wu B, Greenside PG, Chan SM, Koenig JL, Snyder MP, Pritchard JK, Kundaje A, Greenleaf WJ, et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. *Nat Genet* 2016; 48:1193-203; PMID:27526324; <https://doi.org/10.1038/ng.3646>
 42. Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, Biswas D, Roeder RG, Allis CD, Melnick A, et al. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. *Cell Rep* 2013; 3(1):116-27; PMID:23352661; <https://doi.org/10.1016/j.celrep.2012.12.016>